


In the Claims

1.-64. (Cancelled)

65. (Currently Amended) A process for treating fibroses comprising administering a therapeutically effective amount of the a pharmaceutical composition which comprises comprising at least one biocompatible polymer selected from the group consisting of RGTA 1112 (CM₂DPhES₂) and RGTA 1113 (CM₃DTyrS₂) of the following general formula (I):



wherein:

~~A is (O-CH₂-CH₂-CO)-,~~

~~X is COOH or COO⁻Na⁺;~~

~~Y is CO-CH₂-CHOH-CH₂-SO₃H or CO-CH₂-CHOH-CH₂-SO₃⁻Na⁺; and~~

~~Z represents at least one functional chemical group, which is different from X and Y, selected from the group consisting of a fatty acid, amino acid, fatty alcohol, ceramide or derivative thereof and nucleotide addressing sequences and which confers supplementary biological or physiochemical properties, or wherein~~

~~A is a glucose monomer,~~

~~X is CH₂-COOH or CH₂-COO⁻Na⁺;~~

~~Y is SO₃H or SO₃⁻Na⁺; and~~

~~a represents the number of monomers A such that the mass of said polymers of formula (I) is greater than approximately 5,000 da;~~

~~x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%;~~

~~y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%; and~~

~~z represents a substitution rate of the monomers A by the groups Z, which is between approximately 0 and 50%.~~

66.-68. (Cancelled)